Clinical Trial Update: A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC) [Phase 3]

View source ↗

Summary

A Phase 3 study of LT-02 for mesalamine-refractory ulcerative colitis has been terminated, with the study status recorded as TERMINATED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• LT-02

Snippet

Sponsor: Prometheus Laboratories | Conditions: Ulcerative Colitis | Phase 3 | Status: TERMINATED